AbCellera Biologics price to sales ratio ABCL
Market value divided by revenue over the last twelve months, since 2022.
- Today, Nov 2, 2026
- 51.5×
- 5-year median
- 24.0×
- Against its 5-year history
- 93rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 4.0× to 66.0×
- Peer median
- 3.6×
AbCellera Biologics' price to sales ratio is 51.5× as of Nov 2, 2026.
That is above its 5-year median of 24.0×, higher than on 93% of days in the last 5 years.
Over that time it ranged from 4.0× in Apr 2023 to 66.0× in Jul 2025.
The median for 10 large drugmakers of a similar size is 3.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 51.5× | 13.2× | 63.7× |
| 2025 | 30.3× | 21.6× | 66.0× |
| 2024 | 26.8× | 21.3× | 38.9× |
| 2023 | 32.9× | 4.0× | 32.9× |
| 2022 | 4.8× | 4.2× | 7.7× |
Against its peers
Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ABCLAbCellera Biologics | 51.5× |
| OGNOrganon | 0.6× |
| LQDALiquidia | 8.3× |
| ARQTArcutis Biotherapeutics | 8.5× |
| NRIXNurix Therapeutics | 4.0× |
| INDVIndivior Pharmaceuticals | 3.1× |
| PBHPrestige Consumer Healthcare | 2.1× |
| HRMYHarmony Biosciences | 2.3× |
| LGNDLigand Pharmaceuticals | 21.1× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| Peer median | 3.6× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on AbCellera Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.